MedTrace Logo

Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management

NCT01242098 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 137

Last updated 2012-06-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to fluticasone dipropionate / salmeterol (FP/SAL; Seretide® 125) in matched asthma patients switching to BDP/FOR following treatment with FP/SAL in normal clinical practice compared with patients not switched.

Conditions

Interventions

DRUG

Fixed dose combination salmeterol / fluticasone

Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy

DRUG

Fixed-dose combination beclometasone dipropionate / formoterol

Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy

Sponsors & Collaborators

  • Chiesi Farmaceutici S.p.A.

    collaborator INDUSTRY

  • Research in Real-Life Ltd

    lead NETWORK

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01242098 on ClinicalTrials.gov